Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Pre-treatment Metabolic Tumor Volume and Total Lesion Glycolysis are Useful Prognostic Factors for Esophageal Squamous Cell Cancer Patients

  • Li, Yi-Min (Department of Radiation Oncology, the First Affiliated Hospital of Xiamen University) ;
  • Lin, Qin (Department of Radiation Oncology, the First Affiliated Hospital of Xiamen University) ;
  • Zhao, Long (Department of Nuclear Medicine, the First Affiliated Hospital of Xiamen University) ;
  • Wang, Li-Chen (Department of Radiation Oncology, the First Affiliated Hospital of Xiamen University) ;
  • Sun, Long (Department of Nuclear Medicine, the First Affiliated Hospital of Xiamen University) ;
  • Dai, Ming-Ming (Department of Radiation Oncology, the First Affiliated Hospital of Xiamen University) ;
  • Luo, Zuo-Ming (Department of Nuclear Medicine, the First Affiliated Hospital of Xiamen University) ;
  • Zheng, Hua (Department of Radiation Oncology, the First Affiliated Hospital of Xiamen University) ;
  • Wu, Hua (Department of Nuclear Medicine, the First Affiliated Hospital of Xiamen University)
  • Published : 2014.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: To study application of the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) with $^{18}F$-FDG PET/CT for predicting prognosis of esophageal squamous cell cancer (ESC) patients. Methods: Eighty-six patients with ESC staged from I to IV were prospectively enrolled. Cisplatin-based chemoradiotherapy (CCRT) or palliative chemoradiotherapy were the main treatment methods and none received surgery. $^{18}F$-FDG PET/CT scans were performed before the treatment. SUVmax, MTV, and TLG were measured for the primary esophageal lesion and regional lymph nodes. Receiver operating characteristic curves (ROCs) were generated to calculate the P value of the predictive ability and the optimal threshold. Results: MTV and TLG proved to be good indexes in the prediction of outcome for the ESC patients. An MTV value of 15.6 ml and a TLG value of 183.5 were optimal threshold to predict the overall survival (OS). The areas under the curve (AUC) for MTV and TLG were 0.74 and 0.70, respectively. Kaplan-Meier analysis showed an MTV less than 15.6 ml and a TLG less than 183.5 to indicate good media survival time (p value <0.05). In the stage III-IV patient group, MTV could better predict the OS (P < 0.001), with a sensitivity and specificity of 0.80 and 0.67, respectively. Conclusions: Pre-treatment MTV and TLG are useful prognostic factors in nonsurgical ESC.

Keywords

References

  1. Bradley J, Thorstad WL, Mutic S, et al (2004). Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 59, 78-86. https://doi.org/10.1016/j.ijrobp.2003.10.044
  2. Cooper JS, Guo MD, Herskovic A, et al (1999). Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA, 281, 1623-7.
  3. Shen K, Huang XE, Lu YY, et al (2012). Phase II study of docetaxel (Aisu$^{(R)}$) combined with three- dimensional conformal external beam radiotherapy in treating patients with inoperable esophageal cancer. Asian Pac J Cancer Prev, 13, 6523-6. https://doi.org/10.7314/APJCP.2012.13.12.6523
  4. Greene FL (2002). The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg, 87, 13-5.
  5. Hellwig D, Graeter TP, Ukena D, et al (2007). $^{18}F$-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense? J Nucl Med, 48, 1761-6. https://doi.org/10.2967/jnumed.107.044362
  6. Herskovic A, Martz K, al-Sarraf M, et al (1992). Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med, 326, 1593-8. https://doi.org/10.1056/NEJM199206113262403
  7. Hong D, Lunagomez S, Kim EE, et al (2005). Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer, 104, 1620-6. https://doi.org/10.1002/cncr.21356
  8. Hyun SH, Choi JY, Shim YM, et al (2010). Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol, 17, 115-22. https://doi.org/10.1245/s10434-009-0719-7
  9. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  10. Klaeser B, Nitzsche E, Schuller JC, et al (2009). Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). Onkologie, 32, 724-30. https://doi.org/10.1159/000251842
  11. Omloo JM, Sloof GW, Boellaard R, et al (2008). Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer. Endoscopy, 40, 464-71. https://doi.org/10.1055/s-2008-1077302
  12. Rizk N, Downey RJ, Akhurst T, et al (2006). Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg, 81, 1076-81. https://doi.org/10.1016/j.athoracsur.2005.09.063
  13. Ma JB, Chen EC, Song YP, et al (2013). Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography (PET)-based parameters in neoadjuvant chemoradiation treatment of esophageal carcinoma. Asian Pac J Cancer Prev, 14, 2477-81. https://doi.org/10.7314/APJCP.2013.14.4.2477
  14. Roedl JB, Colen RR, Holalkere NS, et al (2008). Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol, 89, 278-86. https://doi.org/10.1016/j.radonc.2008.06.014
  15. Liao S, Penney BC, Zhang H, Suzuki K, Pu Y (2012). Metabolic Tumor Volume Measured by F-18 FDG PET/CT can Further Stratify the Prognosis of Patients with Stage IV Non-Small Cell Lung Cancer. Nucl Med Mol Imaging, 19, 69-77.
  16. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M (1999). Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med, 40, 1771-7.
  17. Westerterp M, Sloof GW, Hoekstra OS, et al (2008). 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol, 134, 227-36. https://doi.org/10.1007/s00432-007-0275-0
  18. Zhu WQ, Sun XR (2011). The prognostic value of metabolic tumor volume in FDG PET/CT evaluation of post-operative survival in patients with esophageal squamous cell cancer[in Chinese]. Chin J Nucl Med, 31, 378-81.

Cited by

  1. Combination of FDG PET/CT and Contrast-Enhanced MSCT in Detecting Lymph Node Metastasis of Esophageal Cancer vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7719
  2. Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer vol.26, pp.2, 2016, https://doi.org/10.1007/s00330-015-3860-7
  3. Correlation between Semi-Quantitative 18F-FDG PET/CT Parameters and Ki-67 Expression in Small Cell Lung Cancer vol.50, pp.1, 2016, https://doi.org/10.1007/s13139-015-0363-z
  4. FDG PET using SUVmax for preoperative T-staging of esophageal squamous cell carcinoma with and without neoadjuvant chemoradiotherapy vol.17, pp.1, 2017, https://doi.org/10.1186/s12880-016-0171-7
  5. F-FDG PET/CT as a Prognostic Factor for Locally Advanced Esophageal Cancer vol.31, pp.1, 2016, https://doi.org/10.3346/jkms.2016.31.1.39
  6. Prediction of Recurrence and Mortality of Locally Advanced Esophageal Cancer Patients Using Pretreatment F-18 FDG PET/CT Parameters: Intratumoral Heterogeneity, SUV, and Volumetric Parameters vol.31, pp.1, 2016, https://doi.org/10.1089/cbr.2015.1932
  7. Importance of 18F-FDG PET/CT to select patients with nonresectable colorectal liver metastases for liver transplantation vol.39, pp.7, 2018, https://doi.org/10.1097/MNM.0000000000000843
  8. Prognostic value of metabolic tumor volume and total lesion glycolysis in esophageal carcinoma patients treated with definitive chemoradiotherapy vol.39, pp.6, 2018, https://doi.org/10.1097/MNM.0000000000000837
  9. Baseline 18F-FDG PET/CT as predictor of the pathological response to neoadjuvant therapy in esophageal cancer vol.97, pp.49, 2018, https://doi.org/10.1097/MD.0000000000013412